Serum leptin in children with asthma treated with inhaled budesonide  by Heuck, C. & Wolthers, O.D.
&4’iRATORY MECKW (1999) 93, 268-271 
Serum leptin in children with asthma treated with 
inhaled budesonide 
C. HEUCK’ AND 0. D. WOLTHERS+ .i< 
*Department 01 Paedi&ics and institute of Experimenta Clinical Research, Medical Research 
Laboratories, Aarhus Unioersify Hospital, Aarhus und ‘Department of Paediatrics, Randers Hospiful, 
Denmark 
Leptin, a 167-amino-acid peptide, is a recently discoverd hormone which is believed to play a major role in the 
regulation of body weight. Systemic administration of exogenous glucocorticoids has been found to increase 
circulating leptin levels. 
In this study, we aimed to assess serum leptin in children with asthma treated with inhaled budesonide 
EiOO,ug day-‘. 
Ten boys and three girls with asthma, all adolescents aged from 12.9 to 16.6 years, were studied in a randomized 
double-blind two-period cross-over trial with 4-week treatment periods and a l-week wash out. Placebo was given 
during one period and 800,~g budesonide during the other via a 750 ml volume spacer (Nebuhaler@, Astra Draco, 
Lund, Sweden). On the last day of the placebo and budesonide periods blood samples were taken and serum leptin 
was measured by a specific radioimmunoassay. 
The difference in mean (SEM) leptin concentration between the budesonide and placebo period was 0.2 (0.4) pg 1 - ’ 
(P=O.71; t= - 0.4; df= 12, 95% confidence interval - 0.9-0.7 lug 1 - ‘). 
Inhaled budesonide 800 ,ug per day from a Nebuhaler@ does not influence circulating leptin levels, suggesting that 
regulation of body weight is unaffected. 
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Introduction 
The recently discovered hormone leptin, a 167-amino-acid 
peptide secreted by adipose tissue, is believed to influence 
appetite, energy homoeostatis and body weight through 
regulation of food intake by a negative feedback signal 
involving the hypothalamic-pituitary-adrenal axis (l-3). 
The suppressive effect of leptin on fat accretion is thought 
to be accompanied by stimulatory effects on energy 
expenditure (24-7). Little is known about the regulation of 
leptin; however, exogenous glucocorticoids have been 
found to increase leptin levels in adults (8-10) and in 
children (11). Since high doses of inhaled glucocorticoids 
may cause systemically detectable effects the aim of the 
present study was to assess serum leptin in asthmatic 
children treated with inhaled budesonide 8OOpg per day 
(12,13). 
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Patients and Methods 
The protocol was part of a clinical study of systemic activity 
of inhaled budesonide in adolescents (14). Ten boys and 
three girls with asthma, aged 12.9-16.6 (mean 14.8) years 
from an outpatient secondary referral center participated in 
the study. All had mild to moderate asthma needing 
treatment as required with inhaled &agonists or low doses 
of inhaled glucocorticoids during intervals of the year. 
None had received treatment with inhaled or oral glucocor- 
ticoids during the month before the study, and no other 
drugs were taken during the study period. All were puber- 
tab according to the Tanner rating of puberty (15). Genital 
development in the boys and breast development in the girls 
varied from stage III to V (stage III: n=3, IV: 11=3, V: n=4) 
and from stage II to III (stage II: n= 1, III: n=2), respect- 
ively. Pubic hair development in the boys varied from stage 
III to V (stage III: n 1, IV: n=7, v: n=2), and in the girls 
from stage II to IV (stage II: n=l, III: n=l, IV: n=2). 
Height at study entry varied from 151.4 to 179.5 (mean 
165.5) cm, height standard deviation score from - 0.8 to 0.7 
(mean - 0.02), weight from 40.5 to 67.0 (mean 52.7) kg, 
and body mass index from 16.0 to 22.3 (mean 18.9). The 
study was approved by the local ethics committee, and 
informed consent was obtained from all children and their 
parents. 
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The design was a randomized double-blind, placebo- 
controlled two-period cross-over trial. After a l-week 
run-in during which no other medication except inhaled 
&agonists was allowed, the children were allocated to two 
4-week treatment periods with a l-week wash-out in 
between. During one period placebo was given and during 
the other 400,ug budesonide was given twice daily. The 
treatment order was allocated by a computerized random- 
ization scheme prepared in balanced blocks. A conven- 
tional pressurized metered dose inhaler was delivered at the 
start of each period. One actuation of the budesonide 
aerosol delivered 2OOpg. The medicine was taken via a 
750 ml volume spacer (the’ Nebuhaler@, Astra Draco, 
Lund, Sweden) at approximately 0730 h and 2130 h. 
On the last day of the placebo and budesonide periods 
blood samples were taken at roughly the same time (that is, 
within 1 h) in the afternoon (between 1300 and 1800 h). 
After centrifugation at 4000 rpm for 10 min within 1 h the 
samples were stored at - 80°C and batch assayed at the 
completion of the study. Serum leptin was measured by a 
commercially available radioimmunoassay (Linco Research 
Inc., St. Louis, MO, U.S.A.) (16). The assay has a detection 
range of 0.22-100 pug 1 - ‘. Intra- and interassay coefficients 
of variation were <S%. 
Statistics 
Data were tested for normal distribution and were found to 
fulfil conditions for parametric analysis. Paired Student’s 
t-test was used for comparison of the data and a 5% level of 
significance was applied. 
Results 
Individual serum leptin concentrations are shown in Fig. 1. 
During budesonide and placebo treatment mean serum 
leptin (SEM) was 4.2 (0.9) and 4.0 (0.9) fig 1 - ‘, respectively. 
The mean difference of 0~2 (0.4) pg 1 - ’ was not statistically 
significant (P=O.71; t= - 0.4; df= 12; 95% confidence 
interval - 0.9-0.7pg 1 - i). 
Discussion 
Leptin is exclusively secreted by differentiated adipocytes 
and serum concentrations correlate with fat mass or body 
mass index (17). Data on the biological effects of leptin 
mainly come from animal experiments showing that leptin 
acts by both suppressing food intake and stimulating 
energy expenditure, including thermogenesis (18). In 
addition to its metabolic effects leptin may interact with 
hormones such as insulin, gonadotrophins, androgens and 
catecholamines and leptin receptors have been identified in 
numerous organs such as the central nervous system, 
kidney, liver, heart and lungs (19,20). The importance of 
the receptors in the lungs, or in any peripheral tissue,. is not 
known; however, it has been suggested that Ieptin may act 
Placebo Budesonide 
FIG. 1. Serum leptin concentrations in 
asthma during treatment with placebo 




as a signal from adipose tissue telling the organism how 
much energy is available from fat stores (21). 
Females have higher leptin levels than males (22). 
Furthermore, a significant diurnal variation in leptin levels 
has been found showing relatively constant levels from 
approximately 1000 h to 1800 h followed by increased levels 
during the night with peak levels between approximately 
2200 h and 0200 h (23,24). In the present study’possible 
influences of diurnal variations in serum leptin were 
avoided since blood was consistently collected from each 
individual child within 1 h during the afternoon. 
The nocturnal rise in leptin levels precedes the early 
morning rise of adrenocorticotrophic hormone (ACTH) 
and cortisol, and short-term variations in endogenous 
cortisol levels do not appear to cause changes’ in leptin 
levels (24,25). Administration of dexamethasone and 
methylprednisolone, however, were associated with in- 
creased circulating leptin levels (8-l 1; unpublished data). 
The stimulating effect was similar in lean and obese indi- 
viduals. The mechanism of glucocorticoid stimulation of 
serum leptin may involve peripheral effects on adipocytes 
and central effects mediated by hypothalamic secretion of 
the neurosecretory agent neuropeptide Y (26). It has 
been suggested that increased leptin secretion may be a 
counter-regulatory response to limit glucocorticoid-induced 
hyperphagia and weight gain (2fj,27). 
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Few studies have assessed lipid metabolism in children 
treated with inhaled glucocorticoids. An increase in 
high-density lipoprotein cholesterol in children treated with 
inhaled budesonide 800,~g has been reported; however, 
clinical implications remain to be clarified (28). Besides case 
reports of weight gain as part of a Cushingoid appearence 
presumably due to an increased sensitivity to exogenous 
glucocorticoids, there are no available data to suggest 
that inhaled glucocorticoids may influence body weight 
(29). In accordance with that we found no effect of inhaled 
budesonide 800 pg on circulating leptin levels. Theoreti- 
cally, this finding could be taken to suggest that the 
systemic bioavailability of inhaled budesonide is very small 
or unimportant. However, the systemic bioavailability of 
inhaled budesonide has been well documented (30). 
Adverse effects of 800 pug budesonide on short-term growth 
and markers of collagen turnover in children have been 
found in studies using comparable designs (13,14). Consid- 
ering that a similar assay was used in studies of dexametha- 
sone (8-11) and, furthermore, that we recently used the 
present assay in a study of methylprednisolone in eight 
children and found elevated leptin levels (unpublished 
data), we do not believe that the present results could have 
been influenced by poor sensitivity in assay or study design. 
So, though long-term effects may not be ruled out from the 
present data we find it safe to conclude that inhaled 
budesonide 800 pug from the Nebuhaler@ does not influence 
circulating leptin levels in children, suggesting that the 
regulation of appetite and body weight is not affected. 
Whether that may also apply to adults in whom the hepatic 
metabolization rate of glucocorticoids is slower than in 
children, or to dry power administration of budesonide 
which causes a greater intrapulmonary deposition resulting 
in a greater systemic bioavailability of the drug, remains to 
be evaluated. 
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